

Chao-Hung Kuo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8065671/publications.pdf>

Version: 2024-02-01

52
papers

1,783
citations

430874

18
h-index

276875

41
g-index

53
all docs

53
docs citations

53
times ranked

2017
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis of <i>Helicobacter pylori</i> infection: Current options and developments. World Journal of Gastroenterology, 2015, 21, 11221.	3.3	292
2	Fecal microbiota transplantation: Review and update. Journal of the Formosan Medical Association, 2019, 118, S23-S31.	1.7	263
3	Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori Infection. Clinical Gastroenterology and Hepatology, 2010, 8, 36-41.e1.	4.4	225
4	Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2009, 63, 1017-1024.	3.0	86
5	Predictive modeling of blood pressure during hemodialysis: a comparison of linear model, random forest, support vector regression, XGBoost, LASSO regression and ensemble method. Computer Methods and Programs in Biomedicine, 2020, 195, 105536.	4.7	69
6	Lansoprazole-based sequential and concomitant therapy for the first-line <i>Helicobacter pylori</i> eradication. Journal of Digestive Diseases, 2012, 13, 232-238.	1.5	64
7	Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2013, 68, 222-228.	3.0	50
8	Silver decorated copper oxide (Ag@CuO) nanocomposite enhances ROS-mediated bacterial architecture collapse. Colloids and Surfaces B: Biointerfaces, 2017, 155, 399-407.	5.0	49
9	Apigenin has anti-atrophic gastritis and anti-gastric cancer progression effects in Helicobacter pylori-infected Mongolian gerbils. Journal of Ethnopharmacology, 2014, 151, 1031-1039.	4.1	42
10	Helicobacter pylori Infection. Medicine (United States), 2011, 90, 180-185.	1.0	41
11	Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy. Helicobacter, 2010, 15, 265-272.	3.5	40
12	Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin Achieves a High Eradication Rate for <i>Helicobacter pylori</i> Infection after Failure of Sequential Therapy. Helicobacter, 2014, 19, 74-79.	3.5	39
13	The Optimal First-Line Therapy of <i>Helicobacter pylori</i> Infection in Year 2012. Gastroenterology Research and Practice, 2012, 2012, 1-8.	1.5	34
14	Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology, 2018, 16, 1427-1433.	4.4	32
15	An Aptamer-Based Capacitive Sensing Platform for Specific Detection of Lung Carcinoma Cells in the Microfluidic Chip. Biosensors, 2018, 8, 98.	4.7	30
16	Stromal C-type lectin receptor COLEC12 integrates H. pylori, PGE2-EP2/4 axis and innate immunity in gastric diseases. Scientific Reports, 2018, 8, 3821.	3.3	28
17	Current Pharmacological Management of Gastroesophageal Reflux Disease. Gastroenterology Research and Practice, 2013, 2013, 1-12.	1.5	27
18	Eight Weeks of Esomeprazole Therapy Reduces Symptom Relapse, Compared With 4 Weeks, in Patients With Los Angeles Grade A or B Erosive Esophagitis. Clinical Gastroenterology and Hepatology, 2015, 13, 859-866.e1.	4.4	23

#	ARTICLE	IF	CITATIONS
19	Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3298-3316.	2.3	19
20	Trend of changes in antibiotic resistance in <i>Helicobacter pylori</i> from 2013 to 2019: a multicentre report from Taiwan. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097699.	3.2	19
21	Eradication of <i>Helicobacter pylori</i> infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2014, 30, 167-172.	1.9	18
22	Comparison of Second-Line Quadruple Therapies with or without Bismuth for <i>Helicobacter pylori</i> Infection. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	18
23	<i>Helicobacter pylori</i> Infection-Induced Hepatoma-Derived Growth Factor Regulates the Differentiation of Human Mesenchymal Stem Cells to Myofibroblast-Like Cells. <i>Cancers</i> , 2018, 10, 479.	3.7	18
24	Suppression of IL-6/ Src signalling axis by 17 β -estradiol inhibits human mesenchymal stem cells-mediated gastric cancer invasion. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 962-972.	3.6	17
25	Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1731-1737.	2.8	17
26	Polymorphism in COX-2 modifies the inverse association between <i>Helicobacter pylori</i> seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. <i>BMC Gastroenterology</i> , 2009, 9, 37.	2.0	16
27	17 β -Estradiol inhibition of IL-6/ Src and Cas and paxillin pathway suppresses human mesenchymal stem cells-mediated gastric cancer cell motility. <i>Translational Research</i> , 2014, 164, 232-243.	5.0	16
28	Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for <i>Helicobacter pylori</i> . <i>Journal of Digestive Diseases</i> , 2017, 18, 537-542.	1.5	16
29	Dual specimens increase the diagnostic accuracy and reduce the reaction duration of rapid urease test. <i>World Journal of Gastroenterology</i> , 2010, 16, 2926.	3.3	16
30	IL-33 regulates M1/M2 chemokine expression via mitochondrial redox-related mitophagy in human monocytes. <i>Chemico-Biological Interactions</i> , 2022, 359, 109915.	4.0	15
31	A Rapid and Accurate Method to Evaluate <i>Helicobacter pylori</i> Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. <i>Medicine (United States)</i> , 2016, 95, e3458.	1.0	13
32	17 β -Estradiol Inhibits Mesenchymal Stem Cells-Induced Human AGS Gastric Cancer Cell Mobility via Suppression of CCL5- Src/Cas/Paxillin Signaling Pathway. <i>International Journal of Medical Sciences</i> , 2014, 11, 7-16.	2.5	12
33	Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2021, 26, e12840.	3.5	11
34	A Better Method for Preventing Infection of Percutaneous Endoscopic Gastrostomy. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 358-363.	1.7	10
35	Short-term Celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. <i>World Journal of Gastroenterology</i> , 2009, 15, 4907.	3.3	10
36	Tailored susceptibility-guided therapy via gastric juice PCR for the first-line <i>H. pylori</i> eradication, a randomized controlled trial. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1450-1457.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Allergic rhinitis is a risk factor of gastro-esophageal reflux disease regardless of the presence of asthma. <i>Scientific Reports</i> , 2019, 9, 15535.	3.3	9
38	Gastric juice-based PCR assay: An alternative testing method to aid in the management of previously treated <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2019, 24, e12568.	3.5	9
39	Immunological map in COVID-19. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 547-556.	3.1	9
40	Postendoscopic retrograde cholangiopancreatography pancreatitis. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 195-201.	1.9	8
41	The Utilization of a New Immunochromatographic Test in Detection of <i>Helicobacter pylori</i> Antibody from Maternal and Umbilical Cord Serum. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	7
42	Significant association between blood lead (Pb) level and haemoglobin A1c in non-diabetic population. <i>Diabetes and Metabolism</i> , 2021, 47, 101233.	2.9	7
43	Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of <i>Helicobacter pylori</i> . <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-6.	1.5	6
44	First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 8395-8404.	3.3	6
45	Current applications of fecal microbiota transplantation in intestinal disorders. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 327-331.	1.9	6
46	<p></p>Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1347-1356.	4.3	5
47	Risks of substance uses, alcohol flush response, <i>Helicobacter pylori</i> infection and upper digestive tract diseases—An endoscopy cross-sectional study. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 341-349.	1.9	3
48	Genetic polymorphisms of <i>CYP2C19</i> and <i>IL1B</i> have no influence on esomeprazole treatment for mild erosive esophagitis. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 255-259.	1.9	2
49	Emergency department infection control strategies in response to <sc>COVID</sc>—19. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 568-569.	1.9	1
50	Evaluating the Validity of the Serologic Test for Detecting <i>Helicobacter pylori</i> Infection in Mongolian Gerbils. <i>Kaohsiung Journal of Medical Sciences</i> , 2007, 23, 545-551.	1.9	0
51	Diabetes care during the outbreak of 2019 novel coronavirus disease (<sc>COVID</sc>—19) in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 658-659.	1.9	0
52	Infection control strategies of patient diversion in response to <sc>COVID</sc>—19. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 765-767.	1.9	0